ICH Project The 27th ICH Informal Debriefing Session

November 02, 2012

The 27th ICH Readiness Briefing Session was held on December 14, 2012 at Yakult Hall in Tokyo to share the outcome of the ICH Regular Meeting held on November 10-15, 2012 in San Diego, U.S.A. with companies in charge of drug development and safety assurance. The meeting was held at Yakult Hall in Tokyo, Japan, on December 14, 2012.

In addition to a general report on the latest developments of the ICH, the symposium featured reports and Q&A sessions by subject matter experts on trends in topics related to electronic standards for the communication of regulatory information, efficacy, safety, and quality. The program, timetable, and presentation materials for this symposium are attached below as files for direct viewing.
Unauthorized copying or reproduction of the attached materials is strictly prohibited.

Date, Time and Location

Date and Time Location
Friday, December 14, 2012, 10:00-16:00 Yakult Honsha Building, 1-1-19 Higashi-Shinbashi, Minato-ku, Tokyo

Information and Program

Information / Program (298KB)

Presentation Materials

Presentations Speakers

00_Opening Remarks (282KB)

Hironobu Saito (Daiichi Sankyo)

01_Latest trend of ICH (201KB)

Yasuko Inokuma (Ministry of Health, Labour and Welfare)

Topic Trends in Electronic Standards for the Communication of Drug Regulatory Information

02_Data items for transmitting E2B (R3) individual case safety report (549KB)

Ayumi ENDO (Japan Health Sciences Agency)

03_M5:Data items and standards for drug dictionary (917KB)

Toru Kimura (GlaxoSmithKline)

Trends in Efficacy Topics

04_E2C(R2): PBRER Step4 Guideline (617KB)

Yoko Hattori (Daiichi Sankyo)

Trends in Safety Topics

05_S1:Carcinogenicity Study (Review) (2,292KB)

Akiyoshi NISHIKAWA (National Institute of Public Health)

06_S10:Photosafety study (546KB)

Kazuhiro Hosoi (Santen Pharmaceutical)

07_M7: Evaluation and management of DNA reactive (mutagenic) impurities in pharmaceuticals to reduce potential carcinogenic risks (698KB)

Masamitsu HONMA (National Institute of Public Health)

Trends in Quality Topics

08_Q3D:Metallic impurities after San Diego meeting (397KB)

Chikako SHIKATA (National Institute of Public Health)

09_Q7:GMP Q&A for bulk pharmaceuticals (1,382KB)

Tetsuhito Baoda (Mochida Pharmaceutical Co., Ltd.)

 

Share this page

TOP